KG207: Modular Design

 
kg-207-v99.png
 
“Trojan” Blood-Brain Barrier (BBB) binding domain that targets TMEM30A receptors and allows for an active cross BBB transport, resulting in a significantly more enhanced penetration of the molecule into the brain


Engineered Ig Fusion protein (IgG-Fc) with an attenuated effector function to reduce ARIA-E&H toxicities and to stabilize the molecule’s half-life in circulation


Toxic Aβ42 Oligomer-binding Natural Peptide which prevents formation of toxic Aβ oligomers and facilitates their clearance from the brain via CSF
 

KG207 is well positioned to become the "best-in-class" therapy to treat mild to moderate Alzheimer Disease